Page 2 - சிரோசிஸ் பெத்துன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சிரோசிஸ் பெத்துன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சிரோசிஸ் பெத்துன் Today - Breaking & Trending Today

Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)


Research Article
Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
Lars T. Fadnes ,
Roles
Conceptualization,
Data curation,
Formal analysis,
Funding acquisition,
Investigation,
Methodology,
Project administration,
Resources,
Software,
Supervision,
Validation,
Visualization,
Writing – original draft,
Writing – review & editing
Roles
Investigation,
Writing – review & editing
Affiliations
Bergen Addiction Research, Department of Addiction Medicine, Haukeland University Hospital, Norway,
Department of Global Public Health and Primary Care, University of Bergen, Norway
Roles
Formal analysis,
Investigation,
Validation,
Writing – review & editing
Affiliations
Bergen Addic ....

New York , United States , Møg Romsdal , Peter Vickerman , Silvia Eiken Alpers , Elin Leirv , Svetlana Skurtveit , Kristin Holmelid , Rafael Alexander Leiva , Lise Eielsen , Lillian Sivertsen , Marianne Cook Pierron , Ewa Joanna Wilk , Christian Ohldieck , Olav Dalgard , Christer Kleppe , Trude Fondenes Eriksen , Martine Leps , Velinda Hille , Nancy Laura Ortega Maldonado , Kjell Arne Johansson , Mette Hegland Nordbotn , Rolf Gjestad , Nina Elisabeth Eltvik , Maria Olsvold , Mirjamee Kretzschmar ,

Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis


Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis
Promising data supports advancing VS-01 into Phase 2a POC study in Acute on Chronic Liver Failure
Versantis, a clinical-stage company developing novel therapies for orphan liver and pediatric diseases, today announced positive results from a Phase 1b clinical trial of VS-01 in decompensated liver cirrhosis. VS-01 was found to be safe and well tolerated in this first-in-human, single ascending and multiple dose study led by Prof. Dr. Jonel Trebicka at the Goethe University Hospital Frankfurt. VS-01 is a potentially lifesaving, multi-organ support therapy that aims to reverse Acute-on-Chronic Liver Failure (ACLF) by enhancing the clearance of ammonia and other toxins from the body. ....

Kostenloser Wertpapierhandel , Meriam Kabbaj , Vincent Foster , Jonel Trebicka , Vincent Forster , Lorenz Pabijan , Mike Sinclair , Goethe University Hospital Frankfurt , Chronic Liver Failure , Goethe University Hospital , Acute On Chronic Liver Failure , Prof Trebicka , Mrs Graf Dirmeier , Mrs Lorenz Pabijan , Rare Pediatric Diseases Designation , வின்சென்ட் வளர்ப்பு , வின்சென்ட் ஃபார்ஸ்டர் , மைக் சின்க்ளேர் , கோதீ பல்கலைக்கழகம் மருத்துவமனை பிராங்க்ஃபர்ட் , நாள்பட்ட கல்லீரல் தோல்வி , கோதீ பல்கலைக்கழகம் மருத்துவமனை , எடுப்போசை ஆன் நாள்பட்ட கல்லீரல் தோல்வி , ரேர் குழந்தை நோய்கள் பதவி ,

Sequana Medical Notice of 2020 Full Year Results and Business Update

Ghent, BELGIUM – 10 March 2021 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021. The management team will host a conference call with live webcast at 02:00 pm CET / 08:00 am EST on the day of the results. The webcast can be accessed by registering via the investors homepage of the Sequana Medical website or by clicking here. To participate in the Q&A, please click here to register. Once registered, you will receive dial-in numbers and a confirmation code. The webcast and conference call will be conducted in English and a replay will be available on the Company’s website shortly thereafter. For more information, please contact: Sequana Medical Lies Vanneste Director Investor Relations Tel: +32 498 05 35 79 Email: IR@sequanamedical.com LifeSci Advisors Chri ....

Malignant Ascites , Heart Failure , Sequana Medical , Refractory Ascites , Liver Disease , Euronext Brussels , இதயம் தோல்வி , கல்லீரல் நோய் ,

Fatty liver disease: Cirrhosis refers to the end stage of the disease causing nosebleeds


Trending
In a study published in the US National Library of Medicine National Institutes of Health, nosebleeds in end stage liver disease masquerading as severe upper gastrointestinal haemorrhage were investigated.
Although rare, severe nosebleeds is a diagnosis that must be considered in patients presenting with signs and symptoms of severe upper gastrointestinal haemorrhage resulting from the end stage of fatty liver disease.
About five percent of epistaxis (nosebleeds) originates from a posterior nasal source. Bleeding in these cases can be especially severe, noted the study.
It continued: “Local therapy such as nasal packing or cauterization is usually sufficient, but continued or intractable haemorrhage may require arterial ligation, embolization or more recently endoscopic ligation. ....

Privacy Notice , Getty Images , Medicine National Institutes , Autoplay Video , Fatty Liver Disease , ப்ரைவஸீ அறிவிப்பு , கெட்டி படங்கள் , மருந்து தேசிய நிறுவனங்கள் , கொழுப்பு கல்லீரல் நோய் ,